Research Topics
Genomes and GenesSpecies | Gottfried E KonecnySummaryAffiliation: University of California Country: USA Publications
| Collaborators
|
Detail Information
Publications
[Retrospective analysis of dose intensity of epirubicin in breast cancer]G Konecny
Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe im Klinikum Grosshadern der Ludwig Maximilians Universität München, Deutschland
Gynakol Geburtshilfliche Rundsch 40:145-52. 2000..We retrospectively determined the administered dose intensity and the relative toxicity and efficacy of an epirubicin-containing regimen in patients with primary or metastatic breast cancer...- Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancerG Konecny
Division of Hematology Oncology, Department of Medicine, University of California at Los Angeles, School of Medicine, Los Angeles, California 90095 1678, USA
Clin Cancer Res 7:1743-9. 2001..The current study tests the hypothesis that elevated expression of uPA and PAI-1 is associated with prognosis and disease progression... - Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancerG Konecny
Division of Hematology Oncology, Department of Medicine, University of California Los Angeles School of Medicine, Los Angeles, CA 90095 1678, USA
Clin Cancer Res 7:2448-57. 2001.... - Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samplesG Konecny
Department of Medicine, University of California, Los Angeles School of Medicine, 90095 1678, USA
Breast Cancer Res Treat 67:223-33. 2001.... - HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancerG Konecny
Department of Medicine, UCLA School of Medicine, 90095 1678, USA
Breast Cancer Res Treat 69:53-63. 2001..In contrast, tumors with strong HER-2/neu overexpression demonstrated increased dose-dependent in vitro sensitivity to both the FEC and CMF regimens... - Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cellsGottfried E Konecny
Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, 12 145 Factor Building, 10945 Le Conte Avenue, Los Angeles, CA 90095 1678, USA
Cancer Res 66:1630-9. 2006..These observations provide a clear biological rationale to test lapatinib as a single agent or in combination with trastuzumab in HER-2-overexpressing breast cancer and in patients with clinical resistance to trastuzumab... - Gemcitabine in combination with trastuzumab and/or platinum salts in breast cancer cells with HER2 overexpressionGottfried E Konecny
University of California Los Angeles, David Geffen School of Medicine, Los Angeles, California 90095 1678, USA
Oncology (Williston Park) 18:32-6. 2004..These findings indicate that trastuzumab plus gemcitabine and trastuzumab plus gemcitabine plus cisplatin or carboplatin are rational combinations to evaluate in clinical trials... - Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancerGottfried E Konecny
Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, and Jonsson Comprehensive Cancer Center, Los Angeles, CA 90095-7077, USA
J Natl Cancer Inst 96:1141-51. 2004..Furthermore, a taxane-containing regimen such as ET may provide a preferential benefit to patients with HER-2/neu-positive tumors... - Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancerMark D Pegram
Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles 90095-7077, USA
J Natl Cancer Inst 96:739-49. 2004.... - Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancerGottfried E Konecny
UCLA Translational Oncology Research Lab, David Geffen School of Medicine, University of California Los Angeles, 2825 Santa Monica Blvd, Suite 200, Santa Monica, CA, 90404 2429, USA
Breast Cancer Res Treat 120:481-9. 2010..However, added benefit of IDD chemotherapy itself was not associated with HER2 or TOP2A status... - Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancerGottfried E Konecny
Division of Hematology Oncology, Department of Biomathematics and Biostatistics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA
Clin Cancer Res 17:1591-602. 2011..PD-0332991 is a selective inhibitor of the CDK4/6 kinases with the ability to block retinoblastoma (Rb) phosphorylation in the low nanomolar range. Here we investigate the role of CDK4/6 inhibition in human ovarian cancer... - Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinomaChintda Santiskulvong
Division of Gynecologic Oncology, Departments of Obstetrics and Gynecology, UCLA David Geffen School of Medicine, Los Angeles, CA 90095 1740, USA
Clin Cancer Res 17:2373-84. 2011..This study evaluates the effect of dual PI3K and mTOR inhibition using NVP-BEZ235 in preclinical models of ovarian cancer as a potential novel therapeutic strategy... - Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patientsGottfried E Konecny
Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095 1678, USA
Clin Cancer Res 10:1706-16. 2004..compare the prognostic significance of VEGF isoforms; and (c). analyze the combined effects of HER-2/neu and VEGF on clinical outcome... - Is there a role for epidermal growth factor receptor inhibitors in breast cancer prevention?Gottfried E Konecny
J Natl Cancer Inst 95:1813-5. 2003